Learning Hub

Dissemination and communication team Kristina Leipuviene SmartSol SIA Position Project manager What is your role in iPROLEPSIS? Dissemination/Communication lead What are your main activities in the project? Leading and planning communication and dissemination activities. SmartSol team also supports networking and clustering with stakeholders. What is your motivation? As leaders of WP6, SmartSol aims to increase awareness of iPROLEPSIS and make it accessible to everyone. We focus on sharing information, raising awareness about psoriatic arthritis, and making a lasting impact through thoughtful planning and engagement with the public. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

< BACK iPROLEPSIS: updates on user research and co-creation Oct 17, 2023 Co-creation sessions for advancing the development of the mIPROLEPSIS app iPROLEPSIS active engagement with users through ongoing co-creation sessions helps to advance the development of the mIPROLEPSIS app, scheduled for delivery before January 2024. In October 2023, the project partner Erasmus MC (EMC) conducted a co-creation session with patient partners to assess the User Interface (UI) of the PDPID-app. The focus was on improving usability, ensuring users’ understanding of expectations and enhancing users’ engagement to minimise missing data. The project partner FACULDADE DE MOTRICIDADE HUMANA (FMH-ULISBOA), is also developing storyboards for the personalised gaming suite . Three co-creation sessions were conducted: one with healthcare professionals and two with patient partners. Project partners The Centre for Research and Technology Hellas (CERTH) and FACULDADE DE MOTRICIDADE HUMANA (FMH-ULISBOA), in collaboration with the clinical partners, worked on identifying movements for the video analysis that will be included in the iPROLEPSIS-PDPID study. Multiple hand gestures and fullbody movements were identified for further assessment. Main points: mIPROLEPSIS App’s general looks and UI were approved by the patient partners; Despite being a data-collection app for research purposes, patients emphasise the significance of reviewing their own data entries; Participants noted a need for enhanced visual cues regarding specific activities in the app. Main points: Personalised gaming suite Smart games meant for disease management need to be highly tailored to the capabilities of the patients; Patients view gaming as a form of relaxation, emphasising the importance of stress-free design; Patient partners expressed interest in the proposed gaming categories. 1/0 PREVIOUS NEXT

< BACK Season's Greetings from iPROLEPSIS Dec 21, 2023 Merry Christmas and Happy New Year! No updates and announcements, simply warmth, joy, health and peace from the iPROLEPSIS consortium to all our community! Thank you for being a part of our journey. merry (1).png merry (1).png 1/1 PREVIOUS NEXT

< BACK Hot topic debate: preventing psoriatic arthritis in patients with psoriasis Nov 13, 2024 Preventing PsA: Insights from the IFPA-WPPA 2024 Conference Conference IFPA-WPPA 2024 Conference At the 7th World Psoriasis & Psoriatic Arthritis (IFPA-WPPA) Conference , experts discussed whether effective treatment for psoriasis (PsO) could help prevent the onset of psoriatic arthritis (PsA). In this session, Prof. Laura Coates highlighted early intervention as a key strategy for PsA prevention. Supporting these efforts, the iPROLEPSIS consortium, active across Europe, is exploring digital, non-pharmacological tools aimed at improving patient outcomes. These include stress management games designed to offer additional support for people with PsO, focusing on prevention beyond medications alone. Alongside iPROLEPSIS, other studies, including the PAMPA study and HIPPOCRATES Prospective Observational Study (HPOS), are investigating early detection and intervention strategies. Digital tools such as the Psorcast app, along with new apps from iPROLEPSIS, are being developed to monitor psoriasis patients for early signs of PsA. These efforts aim to pave the way for more personalised and preventive care approaches. Abstract Can effective treatment of psoriasis (PsO) prevent the development of psoriatic arthritis (PsA)? In a Hot Topic Debate at the 7th World Psoriasis & Psoriatic Arthritis Conference, Dr. Soriano and Dr. Ogdie, both experts in the field, presented contrasting views based on existing research and clinical studies.1 Dr. Soriano argued that biologic treatments for PsO may reduce PsA risk, citing several retrospective studies. On the other hand, Dr. Ogdie argued that current observational data are plagued by biases, making it difficult to conclude whether biologics play a protective role. The session outlined the complexity of this issue, with both speakers agreeing on the need for prospective randomised controlled trials, such as the ongoing PAMPA study, to provide definitive answers. Prof. Laura Coates added that identifying at-risk patients and intervening early to potentially prevent PsA may point to a strategic research approach to address these unanswered questions. Read the full article: https://conferences.medicom-publishers.com/proceedings/proceedings-in-dermatology/7th-ifpa-wppa-conference/preventing-psoriatic-arthritis-in-patients-with-psoriasis/ 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Research on Digital Rheumatology Published in The Lancet eClinicalMedicine May 19, 2025 New Publication Highlights Explainable AI Tools, Digital Biomarkers, and Multimodal Disease Monitoring for PsA A recent paper published in The Lancet eClinicalMedicine presents the iPROLEPSIS initiative as a comprehensive European research effort aimed at transforming the diagnosis and management of psoriatic arthritis (PsA) through digital innovation and patient-centred care . The paper, titled "European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritis", outlines how iPROLEPSIS addresses critical gaps in current PsA care by combining real-world data , wearable sensors , and explainable artificial intelligence (xAI) models. Abstract The shift from traditional to technology-based diagnosis and management of psoriatic arthritis (PsA) represents a significant evolution in patient care. Traditionally, PsA was diagnosed and managed through clinical evaluations, physical examinations, and basic imaging techniques. With the evolution of digital technologies, PsA care is transforming, giving rise to the field of digital rheumatology. In this vein, Europe has invested in research initiatives, like iPROLEPSIS, that could accelerate this transformation and redefine PsA care within a digital world. In this Viewpoint we present the current clinical PsA landscape, highlight the PsA patients’ interaction with the digital world, and showcase the novel iPROLEPSIS digital offerings. The latter scaffold digital rheumatology by identifying PsA key drivers. Moreover, they support personalized PsA risk prediction and improve early PsA detection. Furthermore, they enable precise PsA treatment strategies and digital therapeutics within a novel digital health ecosystem. Read the full paper here: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00175-0/fulltext PIIS2589537025001750 .pdf Download PDF • 1.20MB Lancet publication.png Lancet publication.png 1/1 PREVIOUS NEXT

< BACK Highlights from IFPA 2024 Jun 28, 2024 iPROLEPSIS at IFPA 2024 The 7th World Psoriasis & Psoriatic Arthritis Conference, held on June 27-29, 2024, brought together leading experts and researchers to discuss the latest advancements in psoriasis and psoriatic arthritis. Dr Laura Coates from the University of Oxford discussed the potential to prevent psoriatic arthritis, including the work being done in iPROLEPSIS and HIPPOCRATES IMI. 1/6 PREVIOUS NEXT

< BACK iPROLEPSIS presented to Eli Lilly in the Netherlands Nov 8, 2023 Presentation to Eli Lilly introduces iPROLEPSIS as the next step in personalised psoriatic arthritis care On the 7th of November 2023, Ilja Tchetverikov from CICERO Rheumatology presented the results and prospects of the DEPAR cohort and introduced iPROLEPSIS clinical studies to the representatives of Eli Lilly company in the Netherlands. DEPAR, Dutch south-west Psoriatic Arthritis Registry, is a registry set up by Cicero Rheumatology, a partnership of rheumatologists working in 15 different hospitals in the south-west of the Netherlands. DEPAR, with the participation of well over 900 patients, supports rheumatologists to gain insight into the treatment and course of psoriatic arthritis. The presentation highlighted iPROLEPSIS as a logical next step in the further development of DEPAR, emphasising the project’s vision and aim to explain psoriatic arthritis inflammation through multi-source data analysis, guiding to a novel personalised digital care ecosystem. Slide1.JPG Slide2.JPG Slide6.JPG Slide1.JPG 1/6 PREVIOUS NEXT

< BACK iPROLEPSIS at GRAPPA 2025: Advancing Digital Tools for Psoriatic Arthritis Care Jul 18, 2025 Exploring how digital biomarkers can support hand function assessment in real-world settings iPROLEPSIS participated in the GRAPPA Annual Meeting 2025 , held on 10–12 July in Bogotá, Colombia. Vasilis Charisis (Aristotle University of Thessaloniki – AUTH) presented an overview of the project’s key objectives and emerging results. The talk highlighted how digital biomarkers – captured via smartphone typing dynamics and video-based motor tasks – can support the assessment of hand function in real-world conditions. The session reached approximately 350 stakeholders, including clinicians, researchers, and industry representatives, helping raise awareness of iPROLEPSIS and its goals within the psoriatic disease community. 2.jpg 1.jpg 3.jpg 2.jpg 1/3 PREVIOUS NEXT

< BACK Psoriatic Arthritis Awareness Day Sep 28, 2023 iPROLEPSIS project is joining to celebrate the Psoriatic Arthritis Awareness Day This September 28th, the iPROLEPSIS project is joining to celebrate Psoriatic Arthritis Awareness Day, dedicated to raising awareness of the painful inflammatory disease often linked with psoriasis. iPROLEPSIS is a research and innovation initiative. The project uses cutting-edge technology and AI to develop a novel personalised digital care ecosystem for people with Psoriatic Arthritis. Join us on September 28th and help reshape the future of Psoriatic Arthritis care! https://video.wixstatic.com/video/981fae_b35edf1e5e4144c786e814aec1d1a28f/1080p/mp4/file.mp4 News & Events iPROLEPSIS - events.png News & Events iPROLEPSIS - events.png 1/1 PREVIOUS NEXT

< BACK World Psoriasis Day 2025: Advancing Prevention and Care Oct 29, 2025 On World Psoriasis Day, iPROLEPSIS highlights ongoing efforts to improve early detection, prevention, and digital support for people living with psoriasis and psoriatic arthritis October 29 marks World Psoriasis Day – a day dedicated to raising awareness of the impact psoriasis has on millions worldwide. For many, the condition goes beyond the skin: up to 30% develop psoriatic arthritis , an inflammatory disease that causes joint pain, stiffness, and fatigue, significantly affecting daily life. This year’s World Psoriasis Day video shares how iPROLEPSIS is working to advance psoriatic arthritis prevention and care. Through clinical studies, digital biomarkers, and co-created digital health tools, the project aims to support early detection , timely monitoring , and personalised care . The ongoing PDPID study is developing and validating predictive models for psoriatic arthritis progression, while the iPROLEPSIS digital ecosystem – including the miPROLEPSIS apps, miDashboard for professionals, and lifestyle interventions – is designed together with patients and clinicians to make technology more supportive of everyday care. Its tools – the miPROLEPSIS and miPROLEPSIS-Lite apps, the miDashboard for professionals, and lifestyle interventions such as serious games and personalised recommendations – are co-created with patients and healthcare providers to ensure they are practical, easy to use, and truly supportive of everyday care. On this World Psoriasis Day, iPROLEPSIS stands with everyone living with psoriasis and psoriatic arthritis. Together with clinical and research partners across Europe, the project continues to work toward earlier detection, prevention, and innovative digital solutions to improve lives. Watch the World Psoriasis Day 2025 video here: https://www.youtube.com/watch?v=FvbTCNH9vMY Screenshot 2025-10-29 083418.png Screenshot 2025-10-29 083418.png 1/1 PREVIOUS NEXT

< BACK Designing Exergames for Psoriatic Arthritis: The Spy and Zen Forest Paradigms Feb 4, 2026 New iPROLEPSIS publication presents the co-design of exergames to support physical activity and rehabilitation in psoriatic arthritis A new publication from the iPROLEPSIS project has been published in the proceedings of the 2025 IEEE International Conference on E-health Networking, Application & Services (HealthCom) . Psoriatic arthritis (PsA) is a rheumatic disease affecting the skin and joints and is commonly associated with stiffness, impaired mobility, and chronic pain. In addition to biological treatments, physiotherapy and exercise are often recommended to improve range of motion and physical function. However, low adherence, high costs, and limited engagement frequently reduce the effectiveness of these interventions. The paper presents the design of two exergames – The Spy and Zen Forest – developed as accessible digital tools to complement traditional rehabilitation approaches. Exergames embed therapeutic movements into game mechanics, supporting motivation and consistency in physical activity. Both games were co-designed with 29 experts , including patients with psoriatic arthritis, clinicians, researchers, and technical stakeholders, to ensure alignment with clinical goals, patient needs, and safe physical engagement. In The Spy , players complete physically engaging missions designed to stimulate dynamic body movement and support coordination, mobility, balance, strength, and flexibility. Zen Forest focuses on slow, calm stretching routines inspired by Pilates and Yoga, promoting flexibility, relaxation, and body awareness. Together, the exergames aim to support personalised activity routines and enable clinicians to monitor progress and recommend tailored interventions. Read the full publication: https://zenodo.org/records/18468928 iPROLEPSIS_Zen and Spy.png iPROLEPSIS_Zen and Spy.png 1/1 PREVIOUS NEXT

< BACK ChatGPT in Nutrition: Trends, Challenges and Future Directions Jun 27, 2024 Exploring the Role of AI in Shaping the Future of Personalised Nutrition Introducing our latest iPROLEPSIS publication, "ChatGPT in Nutrition: Trends, Challenges, and Future Directions" , presented at PETRA 2024. This study explores the evolving role of AI in personalized nutrition. Abstract: A healthy and balanced diet is of paramount importance to the physical and psychological well-being of an individual, since unhealthy dietary choices have been linked with the occurrence of non-communicable diseases. Recent technological advances has led to the development of large language models, such as ChatGPT that has been widely adopted as a convenient tool for creating meal plans and obtaining nutritional information. This work aims to provide a thorough review of the scientific work performed so far regarding the use of ChatGPT in the field of nutrition. In this survey, the advantages and limitations of ChatGPT in different aspects of nutrition are pinpointed, while the challenges from the use of ChatGPT in nutrition are identified and discussed. Future research directions are also proposed to assist researchers towards the development of more effective nutrition recommendation systems. Read the full publication: https://zenodo.org/records/13142880 ChatGPT in Nutrition .pdf Download PDF • 620KB 1/1 PREVIOUS NEXT